

SHARE BUYBACK PROGRAM NOVOZYMES A/S B SHARES

July 22, 2011

On February 11, 2011, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.

Under the program Novozymes will buy back B shares for an amount of up to DKK 400 million in the period from February 11, 2011, to December 31, 2011.

The following transactions have been made under the program:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	274,256		225,678,106
July 15, 2011	500	856.91	428,455
July 18, 2011	9,248	860.31	7,956,147
July 19, 2011	13	862.11	11,207
July 20, 2011	2,391	870.98	2,082,513
July 21, 2011	1,000	869.26	869,260
Accumulated under the program	287,408		237,025,688

Transactions related to Novozymes' incentive programs have resulted in a net sale by Novozymes of 2,295 B shares in the period from July 15 to July 21. The shares related to these transactions were not part of the Safe Harbour share buyback program.

With the transactions stated above, Novozymes owns a total of 1,886,227 treasury shares, corresponding to 2.9% of the share capital. The total amount of shares in the company is 65,000,000, including treasury shares.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Investor relations:

Tobias Bjorklund

Tel. (direct): +45 4446 8682

Tel. (mobile): +45 3077 8682

Martin Riise Nielsen

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.